AU2014286123B2 - Mammalian milk osteopontin for enhancing immune responsiveness - Google Patents

Mammalian milk osteopontin for enhancing immune responsiveness Download PDF

Info

Publication number
AU2014286123B2
AU2014286123B2 AU2014286123A AU2014286123A AU2014286123B2 AU 2014286123 B2 AU2014286123 B2 AU 2014286123B2 AU 2014286123 A AU2014286123 A AU 2014286123A AU 2014286123 A AU2014286123 A AU 2014286123A AU 2014286123 B2 AU2014286123 B2 AU 2014286123B2
Authority
AU
Australia
Prior art keywords
osteopontin
opn
mammal
vaccine
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014286123A
Other languages
English (en)
Other versions
AU2014286123A1 (en
Inventor
Sarah S. Comstock
Sharon DONOVAN
Anne Staudt Kvistgaard
Marcia H. Monaco SIEGEL
Peter Langborg WEJSE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arla Foods AMBA
Original Assignee
Arla Foods AMBA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arla Foods AMBA filed Critical Arla Foods AMBA
Publication of AU2014286123A1 publication Critical patent/AU2014286123A1/en
Application granted granted Critical
Publication of AU2014286123B2 publication Critical patent/AU2014286123B2/en
Assigned to ARLA FOODS AMBA reassignment ARLA FOODS AMBA Amend patent request/document other than specification (104) Assignors: ARLA FOODS AMBA
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dispersion Chemistry (AREA)
AU2014286123A 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness Active AU2014286123B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843185P 2013-07-05 2013-07-05
US61/843,185 2013-07-05
EP13175267 2013-07-05
EP13175267.7 2013-07-05
PCT/EP2014/064339 WO2015001092A1 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Publications (2)

Publication Number Publication Date
AU2014286123A1 AU2014286123A1 (en) 2016-01-21
AU2014286123B2 true AU2014286123B2 (en) 2019-02-28

Family

ID=48740972

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014286123A Active AU2014286123B2 (en) 2013-07-05 2014-07-04 Mammalian milk osteopontin for enhancing immune responsiveness

Country Status (18)

Country Link
US (3) US9956283B2 (OSRAM)
EP (1) EP3016673B1 (OSRAM)
JP (1) JP6509833B2 (OSRAM)
KR (1) KR102307002B1 (OSRAM)
CN (1) CN105407910B (OSRAM)
AU (1) AU2014286123B2 (OSRAM)
BR (1) BR112016000067B1 (OSRAM)
CA (1) CA2916821C (OSRAM)
CL (1) CL2015003803A1 (OSRAM)
DK (1) DK3016673T3 (OSRAM)
EA (1) EA034654B1 (OSRAM)
ES (1) ES2656474T3 (OSRAM)
MX (1) MX369925B (OSRAM)
NZ (1) NZ715430A (OSRAM)
PH (1) PH12015502844B1 (OSRAM)
PL (1) PL3016673T3 (OSRAM)
PT (1) PT3016673T (OSRAM)
WO (1) WO2015001092A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095082A1 (en) * 2018-04-25 2019-10-31 Health And Happiness (H&H) Hong Kong Limited Combinations of osteopontin and 2'-fucosyllactose for use as medicaments
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum
CN113424962A (zh) * 2020-09-21 2021-09-24 黑龙江飞鹤乳业有限公司 提高免疫力的营养组分、含有其的食品或保健品及其用途
EP4326758A4 (en) * 2021-04-20 2025-03-19 University of Cincinnati A vaccine adjuvant for infectious diseases
CN113475720B (zh) * 2021-06-15 2023-07-25 合生元（广州）健康产品有限公司 骨桥蛋白在增加肠道菌群多样性和增加肠道短链脂肪酸含量中的应用
CN118632706A (zh) 2022-01-31 2024-09-10 雀巢产品有限公司 包含骨桥蛋白（opn）的组合物
CN117337994A (zh) * 2023-10-11 2024-01-05 黑龙江飞鹤乳业有限公司 功能性组合物及该组合物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
US20050287247A1 (en) * 2003-09-18 2005-12-29 Sorensen Esben S Infant formula

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293492A1 (en) * 1997-06-11 1998-12-17 Martin Berry Cns neuroregenerative compositions and methods of use
PT1244702E (pt) 2000-01-07 2006-08-31 Arla Foods Amba Processo para o isolamento da osteopontina do leite
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
WO2003100007A2 (en) * 2002-05-24 2003-12-04 Schering-Plough Ltd. Eta-1 gene and methods for use
NZ546398A (en) * 2003-09-18 2009-03-31 Arla Foods Amba Infant formula
KR20090123115A (ko) * 2008-05-27 2009-12-02 한국생명공학연구원 오스테오폰틴을 유효성분으로 함유하는 자연살해세포분화용 조성물 및 이를 이용한 분화 방법
WO2012117119A1 (en) * 2011-03-03 2012-09-07 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species
EA201491010A1 (ru) * 2011-12-07 2015-01-30 Арла Фудз Амба Варианты остеопонтина для применения в подавлении или предупреждении опухолевого роста и композиции, содержащие такие варианты остеопонтина

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056405A1 (en) * 1997-06-10 1998-12-17 Whitehead Institute For Biomedical Research A method of modulating immune response with osteopontin
WO2000063241A2 (en) * 1999-04-15 2000-10-26 Children's Medical Center Corporation Methods and compositions for modulating an immune response
US20050287247A1 (en) * 2003-09-18 2005-12-29 Sorensen Esben S Infant formula

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KHAJOEE V ET AL, "Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, vol. 143, no. 2, ISSN 0009-9104, pages 260 - 268 *

Also Published As

Publication number Publication date
JP6509833B2 (ja) 2019-05-08
WO2015001092A1 (en) 2015-01-08
MX369925B (es) 2019-11-25
EA201690057A1 (ru) 2016-07-29
EP3016673B1 (en) 2017-10-25
US9956283B2 (en) 2018-05-01
CL2015003803A1 (es) 2016-08-05
EP3016673A1 (en) 2016-05-11
USRE50281E1 (en) 2025-01-28
US20180289798A1 (en) 2018-10-11
MX2016000107A (es) 2016-06-07
CN105407910B (zh) 2019-12-03
DK3016673T3 (da) 2018-01-29
PH12015502844A1 (en) 2016-03-28
CA2916821C (en) 2023-10-03
KR102307002B1 (ko) 2021-10-05
PT3016673T (pt) 2018-01-30
BR112016000067B1 (pt) 2022-08-30
US20160136268A1 (en) 2016-05-19
PH12015502844B1 (en) 2016-03-28
CA2916821A1 (en) 2015-01-08
NZ715430A (en) 2022-01-28
KR20160030960A (ko) 2016-03-21
EA034654B1 (ru) 2020-03-03
PL3016673T3 (pl) 2018-04-30
ES2656474T3 (es) 2018-02-27
CN105407910A (zh) 2016-03-16
BR112016000067A2 (OSRAM) 2017-09-05
JP2016529217A (ja) 2016-09-23
US10772955B2 (en) 2020-09-15
AU2014286123A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
USRE50281E1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
Renz et al. The immunological basis of the hygiene hypothesis
Olivares et al. Oral intake of Lactobacillus fermentum CECT5716 enhances the effects of influenza vaccination
Perdigon et al. Interaction of lactic acid bacteria with the gut immune system
JP4942831B2 (ja) 抗アレルギー用組成物
Kusumo et al. Lactobacillus plantarum IS-10506 supplementation increases faecal sIgA and immune response in children younger than two years
Wold Immune effects of probiotics
Saliganti et al. Feeding probiotic Lactobacillus rhamnosus (MTCC 5897) fermented milk to suckling mothers alleviates ovalbumin-induced allergic sensitisation in mice offspring
Saliganti et al. Consumption of probiotic Lactobacillus rhamnosus (MTCC: 5897) containing fermented milk plays a key role in development of the immune system in newborn mice during the suckling–weaning transition
US20020009429A1 (en) Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
US20220370519A1 (en) Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
Kim et al. Induction of cytokines and nitric oxide in murine macrophages stimulated with enzymatically digested lactobacillus strains
CN114340666A (zh) 环二核苷酸的新用途
EP0930316A1 (en) Oral product for the prevention and treatment of infectious gastroenteritides in calves
JP6219728B2 (ja) Ｆｏｘｐ３陽性制御性Ｔ細胞とＩＦＮ−γ産生ＩＬ−１０産生Ｔ細胞誘導を指標とした、経口免疫寛容物質スクリーニング方法及び経口免疫寛容増強組成物
Sarabia-Sainz et al. Maillard neoglycans as inhibitors for in vitro adhesion of F4+ of enterotoxigenic Escherichia coli to piglet intestinal cells
Michael et al. Escherichia coli Nissle 1917 enhances efficacy of oral attenuated human rotavirus vaccine in a gnotobiotic piglet model. Vaccines (Basel). 2022; 10 (1): 83
JP2022169350A (ja) 免疫賦活剤
KR20240006134A (ko) 마이코박테리움 파라고르도네를 포함하는 면역 증강용 조성물
WO2025057524A1 (ja) プラズマサイトイド樹状細胞活性化用組成物
Lu Effects of supplemental osteopontin on intestinal development and serum antibody responses to rotavirus vaccination in piglets
Shunk Effect of bovine lactoferrin on T lymphocyte cell phenotype and function and the response to vaccination in the neonatal piglet

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ARLA FOODS AMBA

Free format text: FORMER NAME(S): ARLA FOODS AMBA

FGA Letters patent sealed or granted (standard patent)